Provided by Tiger Trade Technology Pte. Ltd.

Avis Budget

117.71
+2.472.14%
Post-market: 117.03-0.6840-0.58%19:54 EDT
Volume:1.29M
Turnover:151.24M
Market Cap:4.16B
PE:-6.56
High:119.85
Open:114.98
Low:112.36
Close:115.24
52wk High:847.70
52wk Low:85.96
Shares:35.32M
Float Shares:14.85M
Volume Ratio:3.20
T/O Rate:8.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.9408
EPS(LYR):-25.2557
ROE:5800.00%
ROA:2.70%
PB:-1.23
PE(LYR):-4.66

Loading ...

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

GlobeNewswire
·
Jun 14

Avis Budget Issues New Asset-Backed Securities for Fleet Funding

TIPRANKS
·
Jun 13

Avis Budget unit issues USD 650 million in vehicle-backed notes under AESOP program

Reuters
·
Jun 13

Caribou Biosciences: Buy Rating Reaffirmed on Advancing Allogeneic CAR-T Pipeline and EHA Data; $6 Price Target Maintained

TIPRANKS
·
Jun 12

Caribou Biosciences presents ANTLER trial results at EHA

TIPRANKS
·
Jun 11

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

GlobeNewswire
·
Jun 11

Cellectis Unveils Strong Early CAR-T Data for Lasme-cel and Eti-cel at EHA 2026

TIPRANKS
·
Jun 11

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

GlobeNewswire
·
Jun 11

Verra Mobility Faces Federal Securities Lawsuit After 71% Stock Drop Following Avis Budget Group Termination Notice

TIPRANKS
·
Jun 11

Cellectis Gains FDA RMAT Status for Allogeneic CAR-T lasme-cel in r/r B-ALL

TIPRANKS
·
Jun 10

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

GlobeNewswire
·
Jun 10

Avis Budget Group Is Maintained at Underweight by JP Morgan

Dow Jones
·
Jun 09

What Cencora (COR)'s Expanded Role in Kite CAR T Distribution Means For Shareholders

Simply Wall St.
·
Jun 09

Cartesian Therapeutics Announces In Vivo CAR-T Licensing Alliance

TIPRANKS
·
Jun 09

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

GlobeNewswire
·
Jun 09

Avis Budget price target raised to $155 from $140 at JPMorgan

TIPRANKS
·
Jun 09

Avis Budget Group Inc : JP Morgan Raises Target Price to $155 From $140

THOMSON REUTERS
·
Jun 09

Avis Budget Group Inc. : Barclays Raises to Equal-Weight From Underweight

THOMSON REUTERS
·
Jun 09

U.S. RESEARCH ROUNDUP- Apple, Lennar, Toll Brothers

Reuters
·
Jun 09

Imugene Wins FDA Fast Track for Off-the-Shelf CAR T in CLL/SLL and MZL

TIPRANKS
·
Jun 09